Absence of Growth Retardation in Children With Perennial Allergic Rhinitis After One Year of Treatment With Mometasone Furoate Aqueous Nasal Spray

Abstract

ABSTRACT. Objective. Intranasal corticosteroids are used widely for the treatment of allergic rhinitis because they are effective and well tolerated. However, their potential to suppress growth of pediatric subjects with allergic rhinitis continues to be a concern, particularly in light of reports of growth suppression after treatment with intranasal beclomethasone dipropionate or intranasal budesonide (see the article by Skoner et al in this month's issue).A 1-year study of prepubertal patients between 3 and 9 years of age with perennial allergic rhinitis was conducted to assess the effects on growth of mometasone furoate aqueous nasal spray (MFNS), a new once-daily (QD) intranasal corticosteroid with negligible bioavailability.Methods. This was a randomized, placebo-controlled, double-blind, multicenter study. Ninety-eight subjects were randomized to treatment with either MFNS 100 g QD or placebo for 1 year. Each subject's height was required to be between the 5th and 95th percentile at baseline, and skeletal age at screening was required to be within 2 years of chronological age, as determined by left wrist x-rays. Washout periods for medications that affect either childhood growth or allergic rhinitis symptoms were established based on estimated period of effect, and these medications were prohibited during the study. However, short courses of either oral prednisone lasting no longer than 7 days or low-potency topical dermatologic corticosteroids lasting no longer than 10 days were permitted if necessary.Height was measured with a calibrated stadiometer at baseline and at 4, 8, 12, 26, 39, and 52 weeks, and the primary safety variable was the change in standing height. The rate of growth was also calculated for each subject as the slope (linear regression) of the change in height from baseline using data from all visits of subjects who had at least 2 visits. Hypothalamic-pituitary-adrenocortical-(HPA)-axis function was assessed via cosyntropin stimulation testing at baseline and at 26 and 52 weeks. All analyses were based on all randomized subjects (intent-to-treat principle). The change from baseline in standing height was analyzed by a 2-way analysis of variance that extracted sources of variation attributable to treatment, center, and treatment-by-center interaction.Results. Demographic characteristics were similar at baseline. Eighty-two subjects completed the study (42 in the MFNS group and 40 in the placebo group), and 93% of subjects achieved at least 80% compliance with therapy. After 1 year of treatment, no suppression of growth was seen in subjects treated with MFNS, and mean standing heights were similar for both treatment groups at all time points. For the primary safety variable (change in height from baseline), both treatment groups were similar at all time points except for weeks 8 and 52. Subjects treated with MFNS had a slightly greater mean increase in height than subjects treated with placebo at these time points: the change in height was 6.95 cm versus 6.35 cm at the 1-year time point. Ho...

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

“…Intranasal corticosteroids are more effective than antihistamines and the use of new, selective formulations with less bioavailability is not associated with growth retardation or other significant systemic side effects in children [54][55][56]. AR treatment using corticosteroids was found to improve asthma at best moderately, in some but not all studies.…”

Intranasal Triamcinolone and Growth Velocity

“…[15][16][17][18] Treatment with fluticasone propionate, 15 budesonide, 16 and mometasone furoate 17 aqueous nasal sprays showed no significant differences in GVs after 1 year of treatment using study designs that did not conform to the FDA guidelines for evaluating effects of INCs on growth of children. In contrast, significantly lower growth rates were observed with beclomethasone dipropionate (BDP) 18 and fluticasone furoate nasal spray (unpublished data conforming to FDA guidelines).…”

Place of Topical Steroid Therapy in the Treatment of Acute Rhinosinusitis

“…Эти результа-ты согласуются с чрезвычайно низкой биодоступностью МФ после интраназального введения. В рекомендованной дози-ровке МФ не проявляет системный эффект [29,50,[56][57][58].…”